Terns Pharmaceuticals, Inc. (TERN)

NASDAQ: TERN · IEX Real-Time Price · USD
4.54
-0.06 (-1.30%)
Aug 19, 2022 4:00 PM EDT - Market closed
-1.30%
Market Cap 170.77M
Revenue (ttm) 1,000,000
Net Income (ttm) -53.79M
Shares Out 37.61M
EPS (ttm) -2.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 116,683
Open 4.61
Previous Close 4.60
Day's Range 4.39 - 4.77
52-Week Range 1.45 - 13.77
Beta n/a
Analysts Buy
Price Target 4.59 (+1.1%)
Earnings Date Aug 15, 2022

About TERN

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor b... [Read more...]

Industry Biotechnology
IPO Date Feb 5, 2021
Employees 41
Stock Exchange NASDAQ
Ticker Symbol TERN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for TERN stock is "Buy." The 12-month stock price forecast is 4.59, which is an increase of 1.10% from the latest price.

Price Target
$4.59
(1.10% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Terns Announces $65 Million Oversubscribed Offering

FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors

FOSTER CITY, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

All You Need to Know About Terns Pharmaceuticals, Inc. (TERN) Rating Upgrade to Buy

Terns Pharmaceuticals, Inc. (TERN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL Internat...

-Oral presentation of data from Phase 1 first-in-human trial of TERN-501, demonstrating treatment was well-tolerated and resulted in significant dose-dependent effects on key target engagement biomarkers

3 Stocks Under $2 Insiders Are Aggressively Buying

US crude oil futures traded higher this morning on Thursday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: BARKRCRT

Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022

FOSTER CITY, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer

-  Dr. Russell to report to Dr. Erin Quirk, President and Head of Research & Development

Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates

-IND opened for NASH Phase 2a trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist); trial initiated with top-line data expected in second half of 2023

Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

FOSTER CITY, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...

Terns Reports Topline Results from Early-Stage NASH Study

Terns Pharmaceuticals Inc (NASDAQ: TERN) reported topline results from Part 1 of Phase 1b AVIATION Trial of TERN-201 for treating patients with non-alcoholic steatohepatitis (NASH).   Part 1 of the AVIA...

Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201

FOSTER CITY, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...

7 Biotech Stocks With Key Catalysts in March

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on Investor...

Other symbols: AKBAAMLXASNDBMYIMRA

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

-Top-line data readout from TERN-201 (VAP-1 inhibitor) clinical trial in NASH expected in March 2022

Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D.

FOSTER CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference

FOSTER CITY, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

-Top-line data readout from TERN-201 (VAP-1) clinical trial in NASH expected in 1Q 2022

Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digit...

Oral presentation of data from Phase 2a LIFT Trial of TERN-101, demonstrating differentiated safety and efficacy profiles

Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experien...

FOSTER CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference

FOSTER CITY, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D.

FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...

Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

-  TERN-201 is a highly selective VAP-1 inhibitor intended to address chronic liver inflammation and fibrosis in NASH

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...

Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

FOSTER CITY, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

FOSTER CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist

Terns Pharmaceuticals Inc (NASDAQ: TERN) reported top-line results from the Phase 2a LIFT trial of TERN-101, a liver-distributed farnesoid X receptor (FXR) agonist for the treatment of patients with non...